Predicting Toxic Monomer Components in Polygonum multiflorum Based on Quantitative Structure-activity Relationship

doi:10.19803/j.1672-8629.2021.04.12

Abstract

Abstract: Objective To evaluate the toxicity risks of 39 compounds in Polygonum multiflorum based on the quantitative structural-activity relationship, and provide reference for the screening and experimental evaluation of the toxic components. Methods According to the structures of parent nucleus, the compounds were divided into three categories: anthraquinone, anthrone and stibene glucosides. The structures were imported into Toxicity Estimation Software Tool toxicity estimation software tool, (TEST) and Derek Nexus. Oral toxicity LD50 and development toxicity of rats were the prediction endpoints for TEST All the toxicity prediction endpoints (including liver toxicity, nephrotoxicity, cardiotoxicity, neurotoxicity, irritation, phototoxicity and sensitization) except in vitro and in vivo mutagenicity, chromosomal damage and carcinogenicity were chosen to predict their potential toxicity targets and related alert structures. Results Oral toxicity LD50: the LD50 of 18 anthraquinone compounds ranged from 453.5 to 3 574.2 mg/kg, while that of 16 dianthrone monomers ranged from 125.3 to 1 239.6 mg/kg. Development toxicity: ω-hydroxyemodin and hydroxyemodin demonstrated the highest predictive value, followed by epicatechin and catechin. Toxicity targets and related alert structures: all the anthraquinone compounds were considered hepatotoxic, except for 6-methyl-1,3,8-trihydroxy-10H-anthracene-9-one, and they were predicted with the risks of photosensitization and skin sensitization, while the alert structures varied. All the stibene glucosides, except 2,3,5,4'-tetrahydroxy stilbene-2, 3-2-O-β-D -glucoside, showed the risk of thyroid gland toxicity. Most of the dianthrone monomers were photosensitive and skin-sensitizing, while catechin and epicatechin also had the risk of skin sensitization. Conclusion This study may shed light on the screening of toxic components of Polygonum multiflorum, targeted organs and the mechanism of different compound.

Key words: Polygonum multiflorum, LD50, hepatotoxicity, development toxicity, Derek Nexus, TEST

CLC Number:

R996

WANG Qi, YAN Ming, MA Shuangcheng, WEN Hairuo. Predicting Toxic Monomer Components in Polygonum multiflorum Based on Quantitative Structure-activity Relationship[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 352-355.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2021.04.12

https://zgywjj.magtechjournal.com/EN/Y2021/V18/I4/352

References

[1] National Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China Volume 1[M]. Beijing China Pharmaceutical Science and Technology Press(中国医药科技出版社), 2015.
[2] Yan YJ, Dan M, Wang Q, et al.Hepatotoxicity evaluation of polygonum multiflorum based on 2D and 3D hepatocyte models in vitro[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2019, 16(7): 385-392.
[3] Wang Q, Dai Z, Zhang YJ, et al.Study on the hepatotoxicity of dianthrones in Polygoni Multiflori Radix[J].Chin J Pharm Anal.(药物分析杂志), 2018, 38(2): 268-274.
[4] Jiang M, Li Z, He YS, et al.Hepatotoxic assessment of Polygoni Multiflori Radix extract and toxicokinetic study of stilbene glucoside and anthraquinones in rats[J]. Journal of Ethnopharmacology, 2015, 162: 61-68.
[5] Bironaite D, Ollinger K.The hepatotoxicity of rhein involves impairment of mitochondrial functions[J]. Chem Biol Interact, 1997, 103(1): 35-50.
[6] Yu RL, Men WJ, Zhou K, et al.Research progress in toxic material basis and hepatotoxicity mechanism of polygonum multiflorum[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(8): 496-503.
[7] Zhang Y, Wang N, Zhang M, et al.Metabonomics study on polygonum multiflorum induced liver toxicity in rats by GC-MS[J]. Int J Clin Exp Med, 2015, 8(7): 10986-10992.
[8] Wang Q, Dai Z, Zhang YJ et al. The research of the hepatotoxicity of Polygonum multiflorum on the basic of the inhibition of the UGT1A1 enzyme in vivo and in vitro[J]. Chin Pharm J.(中国药学杂志), 2016, 51(22): 1929-1933.
[9] Bai ZF, Gao Y, Zuo XT, et al.Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury[J]. Acta Pharmaceutica Sinica.(药学学报), 2017, 52(7): 1019.
[10] Dai CM.Study on correlation between toxicity and effect of anthraquinone and tannin extracted from rhubarb on HK-2 cells[D]. Chengdu University of TCM (成都中医药大学), 2011.
[11] Qi Wang, Yadan Wang, Yong Li, et al.Identification and characterization of the structure-activity relationships involved in UGT1A1 inhibition by anthraquinone and dianthrone constituents of Polygonum multiflorum[J].Scientific Reports, 2017, 7(1): 17952.
[12] Dodd DE, Layko DK, Cantwell KE, et al.Subchronic toxicity evaluation of potassium bromate in fischer 344 rats.[J] Envir- onmental Toxicology & Pharmacology, 2013, 36(3): 1227-1234.

[1]	YANG Yifan, YANG Yanwei, ZHANG Di, XIE Yin, ZHANG Yong, CHEN Xulin, GAO Sutao, GENG Xingchao, QU Zhe. Quality Control and Test Methods of Human Induced Pluripotent Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 728-734.
[2]	SUN Yinghao, ZANG Shuangyao, YU Wenhui, GUO Shuai, LI Tingting, ZHANG Yi, ZHANG Tingjian, MENG Fanhao. Effects and Challenges of Pharmacology and Toxicology of Aconitum Diterpenoid Alkaloids [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 601-607.
[3]	ZHU Lei, ZHANG Xian, WANG Ruiyan, LI Ying. Adverse Reactions Reports about Tislelizumab Injection in 447 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 649-653.
[4]	ZHENG Kaifan, LENG Hongxu, XU Kaixuan, CAI Wenlu, ZHANG Ying, ZHAO Pengfei, TAN Shengjie, XIN Guizhong. Research Progress on Intestinal Safety of Anthraquinone Laxatives [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 708-713.
[5]	CHEN Runji, SUN Xiaorui, HUANG Xin, JIANG Zhenzhou, ZHANG Luyong, WANG Xinzhi, DING Jian. Dynamic Immunophenotyping of NK Cells in Triptolide-Induced Hepatotoxicity [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 517-522.
[6]	LIU Sihan, PEI Yusheng, TAN Dejiang, SUN Huimin, ZHANG Heng, LIU Tao, WANG Dongmei, HE Qing. Research Progress in Detection Methods of Pyrogen and Bacterial Endotoxin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 361-367.
[7]	CHEN Chen, ZHAO Xiaoyan, CAI Tong, PEI Yusheng. Detection of Bacterial Endotoxin in Recombinant Follicle-Stimulating Hormone β Injection Using Gel-Clot Method and Recombinant C-Factor Method [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 372-376.
[8]	YU Kunzi, KANG Shuai, ZHANG Nanping, CHANG Yan, CHENG Xianlong, WEI Feng. Determinants of Microscopic Identification between Ophiopogonis Radix and Liriopes Radix [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 391-396.
[9]	LIAO Mengfan, ZHONG Liling, XU Yan, LIU Ying, ZHANG Yexiang, CHEN Qingsong, LIU Xudong. Adverse Reactions to Antihypertensive and Hypoglycaemic Drugs Based on Spontaneous Presentation Systems [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 286-291.
[10]	TANG Qianhui, ZHANG Haoran, ZHANG Luyong, JIANG Zhenzhou. Research Progress in Triptolide-Induced Live Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 121-127.
[11]	LIU Biqing, ZHANG Xiaotong, WANG Ke, XING Xiaoxuan, WANG Zhizhou, ZHUANG Wei, ZHANG Qingxia, ZHANG Lan, LI Xiaoling, DONG Xianzhe. Adverse Drug Reaction in 385 Elderly Inpatients with Bacterial Pneumonia under Polypharmacy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 206-210.
[12]	PEI Yusheng, XU Lin, ZHAO Yuxin, CAI Tong, HUA Xiaodong. Low Endotoxin Recovery and Mitigation Strategies [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 72-75.
[13]	ZHAO Qiuyue, WEI Hongtao, LI Dandan, YAN An, DI Xuan. Adverse Reactions of Argatroban in the Treatment of Ischemic Stroke Leading to Gastrointestinal Bleeding [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 88-92.
[14]	WEI Manli, LYU Linyan, ZHENG Zhiyuan, YIN Jiye, MAI Zhixiong. Preclinical genotoxicity evaluation of xueshuantong injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1014-1018.
[15]	LU Jing, YU Shanshan, TONG Fei, LIN Zhuohui, SONG Luyao. One case of severe constipation caused by dapagliflozin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1071-1074.